The percentage of patients who showed an increase in posterior RNP from baseline increased over time in all @ groups , but at a faster rate in the sham group , resulting in statistically significant differences at every time point between months @ ( @ % vs. @ % ; P = @ ) and @ ( @ % vs. @ % ; P < @ ) for ranibizumab @ mg versus sham and from months @ ( @ % vs. @ % ; P = @ ) through @ ( @ % vs. @ % ; P < @ ) for ranibizumab @ mg .